Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lotensin HCT · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg |
| 2 | ACTIVE_COMPARATOR | Lotensin HCT® Tablets 20 mg/25 mg |
| Name | Type | Description |
|---|---|---|
| Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
| Lotensin HCT® Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
Inclusion Criteria: * 1\. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum -human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening...
Lotensin HCT is a combination of benazepril hydrochloride and hydrochlorothiazide, studied in healthy volunteers. It is being developed by Viatris Inc. (VTRS) and is currently in Phase 1 clinical development. The drug is a small molecule and has been evaluated in two completed trials.
Lotensin HCT is developed by Viatris Inc., which trades under the ticker VTRS. The company has conducted clinical trials to evaluate the drug in healthy volunteers. As of now, Lotensin HCT is in Phase 1 development, with two completed studies.
Lotensin HCT is in Phase 1 clinical development. It has completed two Phase 1 trials, both involving healthy volunteers. The drug is investigational and has not been approved by regulatory authorities. Viatris Inc. (VTRS) is the developer of this small molecule.
Lotensin HCT has been studied in two completed Phase 1 trials: NCT00649038, a fed study comparing benazepril HCl and hydrochlorothiazide tablets 20 mg/25 mg to Lotensin HCT tablets, and NCT00649597, a fasting study with the same comparison. Both trials enrolled healthy adults in the United States.
Lotensin HCT is a combination product containing benazepril hydrochloride and hydrochlorothiazide. Clinical trials have compared generic benazepril HCl and hydrochlorothiazide tablets to Lotensin HCT tablets to assess bioequivalence. The drug is being developed by Viatris Inc. (VTRS) and is in Phase 1.